<DOC>
	<DOCNO>NCT01497431</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose Se-methyl-seleno-L-cysteine selenomethionine prevent prostate cancer healthy participant . Chemoprevention use certain drug keep cancer forming . The use Se-methyl-seleno-L-cysteine selenomethionine , two different type selenium compound , may prevent prostate cancer forming .</brief_summary>
	<brief_title>Se-Methyl-Seleno-L-Cysteine Selenomethionine Preventing Prostate Cancer Healthy Participants</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine individual toxicity profile Se-methyl-seleno-L-cysteine ( methyl selenocysteine ; MSC ) selenomethionine ( SeMet ) administer cohort men daily twelve week , dose escalation successive cohort . SECONDARY OBJECTIVES : I . To measure pharmacokinetics selenium , accord form ( MSC v SeMet ) : MSC SeMet impact plasma , albumin , urinary concentration selenium 48 hour dose day 1 84 . II . To evaluate pharmacodynamics selenium form ( MSC v SeMet ) : plasma , albumin , urinary Selenoprotein P ( Sepp1 ) concentration glutathione peroxidase ( GPx ) activity 48 hour dose day 1 84 . III . To store plasma form element ( red cell plus platelet ) future analysis methyl selenol key selenium specie , assay become available . OUTLINE : This dose-escalation study . Participants randomize 1 3 treatment arm . ARM I : Participants receive Se-methyl-seleno-L-cysteine orally ( PO ) day 1-84 . ARM II : Participants receive selenomethionine PO day 1-84 . ARM III : Participants receive placebo PO day 1-84 . After completion study treatment , patient follow day 112 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<mesh_term>Selenomethylselenocysteine</mesh_term>
	<criteria>Total body weight 50 115 kg ( 110 250 lb ) Hemoglobin ( Hgb ) &gt; 12 mg/dL Platelet count &gt; 100,000/μL Absolute neutrophil count ( ANC ) &gt; 1000/μL Creatinine = &lt; institutional upper limit normal ( ULN ) Serum glutamate pyruvate transaminase ( SGPT ) serum glutamic oxaloacetic transaminase ( SGOT ) &lt; 2.0 x ULN Total bilirubin = &lt; ULN ( participant high level bilirubin presume due familial metabolism consider individual basis ) Life expectancy great 3 year Participants must agree use adequate contraception ( barrier method birth control ; abstinence ) time screen study completion ( i.e. , least 2 week last dose study drug ) Ability understand willingness sign write informed consent document Agree refrain use selenium ( Se ) supplement ( 100 mcg dose common multivitamin ) Secontaining drug study 30 day study drug initiation Day 84 Not willing remain Roswell Park Cancer Institute ( RPCI ) , follow , require Presence medical condition , opinion investigator , would place either participant integrity data risk Serum creatinine &gt; ULN , SGOT SGPT &gt; = 2.0 x ULN , bilirubin &gt; ULN Treatment investigational drug within 30 day prior dose study drug Use selenium [ Se ] supplement great 100 mcg dose common multivitamin 30 day study drug initiation Day 84 History allergic reaction attribute compound similar chemical biologic composition investigational agent ( e.g. , reaction Se supplement ) Participants donate 1 unit blood within 30 day prior first dose investigational agent Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 1 Diagnosed cancer , nonmelanoma skin cancer , last 2 year Under treatment cancer Use glucoselowering agent condition would make fast 10:00 pm even 11:00 day 1 84 hazardous American Urological Association ( AUA ) total symptom score &gt; 10 individual symptom score great equal 4 Psychiatric illness would prevent compliance intervention would prevent patient provide informed consent Medical condition opinion treat physician would make protocol unreasonably hazardous participant</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>